Literature DB >> 3131811

Progress in drug therapies for HIV infection.

S Broder1, A S Fauci.   

Abstract

The discovery of effective therapies for HIV requires a fundamental knowledge of retroviral infections. Research by the Public Health Service and collaborating organizations on oncogenic viruses, including retroviruses, has provided much of the basic understanding of retroviruses in general and anti-retroviral therapeutic strategies in particular. Early work by the Viral Cancer and Developmental Therapeutic Programs of the National Cancer Institute and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases has contributed much of the current understanding of AIDS and its therapy. This paper describes the progress that has been made in the treatment of AIDS and the programs that have been created to develop future therapies. These programs include efforts to screen existing compounds for activity against HIV, to design new anti-HIV therapies, and to test potential agents in controlled clinical trials. As a result of these activities, researchers have identified one drug, AZT, that has proven effective in prolonging the lives of some patients with AIDS, and are developing several other promising compounds. The key question no longer is whether HIV infection can be treated, but what is the best and fastest way to develop new therapies and improve existing ones.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131811      PMCID: PMC1478070     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  10 in total

1.  HIV infection is blocked in vitro by recombinant soluble CD4.

Authors:  R A Fisher; J M Bertonis; W Meier; V A Johnson; D S Costopoulos; T Liu; R Tizard; B D Walker; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

2.  Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

Authors:  A Traunecker; W Lüke; K Karjalainen
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

3.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.

Authors:  R E Hussey; N E Richardson; M Kowalski; N R Brown; H C Chang; R F Siliciano; T Dorfman; B Walker; J Sodroski; E L Reinherz
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

Review 4.  AIDS: immunopathogenic mechanisms and research strategies.

Authors:  A S Fauci
Journal:  Clin Res       Date:  1987-10

5.  Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors:  E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

6.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

7.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.

Authors:  D H Smith; R A Byrn; S A Marsters; T Gregory; J E Groopman; D J Capon
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

10.  A soluble form of CD4 (T4) protein inhibits AIDS virus infection.

Authors:  K C Deen; J S McDougal; R Inacker; G Folena-Wasserman; J Arthos; J Rosenberg; P J Maddon; R Axel; R W Sweet
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

  10 in total
  3 in total

1.  Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.

Authors:  Mark M Manak; Dmitry A Moshkoff; Lequan T Nguyen; John Meshki; Pablo Tebas; Florin Tuluc; Steven D Douglas
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

Review 2.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970

3.  Potential benefit of dolutegravir once daily: efficacy and safety.

Authors:  Alessandra Fantauzzi; Ombretta Turriziani; Ivano Mezzaroma
Journal:  HIV AIDS (Auckl)       Date:  2013-02-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.